Adverse outcome in patients who undergo curative surgical resection of rectal and colonic carcinoma results from local recurrence or emergence of initially occult distant metastases. Molecular methodologies offer new approaches to evaluate the status of resection margins and the metastatic phenotype in primary tumors. Polymerase chain reaction with cloning into bacteriophage vectors for further expansion permits detection of DNA from one mutant cancer cell among thousands of non-neoplastic cells. Representational difference analysis (RDA) provides the ability to identify and characterize amplifications which may be prognostic markers in tumors. The hypotheses to be tested in this project are: l. Microscopically occult neoplastic cells at the surgical margins of rectal cancer patients can be detected by molecular genetic analysis, thereby serving as markers for recurrence. 2. Amplified genes in primary colorectal carcinomas are markers for poor prognosis.
Our specific aims for this project are to: l. Evaluate mutations in ras and p53 genes in margin tissue and pelvic irrigation specimens collected after curative resection of rectal carcinomas. Molecular genetic results will be related to histopathologic findings, recurrence, and survival. 2. Apply representational difference analysis (RDA) to pairs of matched metastatic and non-metastatic primary colorectal carcinomas. RDA probes detecting amplifications will be cloned, mapped, and used to search for target genes. The amplifications will be evaluated as prognostic markers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA062924-08S2
Application #
6502411
Study Section
Project Start
2001-05-04
Project End
2002-06-30
Budget Start
Budget End
Support Year
8
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Christmas, Brian J; Rafie, Christine I; Hopkins, Alexander C et al. (2018) Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs. Cancer Immunol Res 6:1561-1577
Blair, Alex B; Murphy, Adrian (2018) Immunotherapy as a treatment for biliary tract cancers: A review of approaches with an eye to the future. Curr Probl Cancer 42:49-58
Raman, Aadhithya; Lennon, Anne Marie (2018) Cyst Fluid Biomarkers - Diagnosis and Prediction of Malignancy for Cystic Lesions of the Pancreas. Visc Med 34:178-181
Noë, Michaël; Pea, Antonio; Luchini, Claudio et al. (2018) Whole-exome sequencing of duodenal neuroendocrine tumors in patients with neurofibromatosis type 1. Mod Pathol 31:1532-1538
Cohen, Joshua D; Li, Lu; Wang, Yuxuan et al. (2018) Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science 359:926-930
Shumar, Stephanie A; Kerr, Evan W; Geldenhuys, Werner J et al. (2018) Nudt19 is a renal CoA diphosphohydrolase with biochemical and regulatory properties that are distinct from the hepatic Nudt7 isoform. J Biol Chem 293:4134-4148
Li, Yuguo; Qiao, Yuan; Chen, Hanwei et al. (2018) Characterization of tumor vascular permeability using natural dextrans and CEST MRI. Magn Reson Med 79:1001-1009
Saung, May Tun; Muth, Stephen; Ding, Ding et al. (2018) Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer. J Immunother Cancer 6:118
Canto, Marcia Irene; Almario, Jose Alejandro; Schulick, Richard D et al. (2018) Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 155:740-751.e2
Makohon-Moore, Alvin P; Matsukuma, Karen; Zhang, Ming et al. (2018) Precancerous neoplastic cells can move through the pancreatic ductal system. Nature 561:201-205

Showing the most recent 10 out of 883 publications